Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis

Abstract Background Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited. The objective of this study was to determine the treatment outcomes of RTX in adults with FSGS and MCD. M...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Panupong Hansrivijit, Wisit Cheungpasitporn, Charat Thongprayoon, Nasrollah Ghahramani
Format: Artigo
Idioma:Inglês
Publicat: BMC 2020-04-01
Col·lecció:BMC Nephrology
Matèries:
Rituximab
FSGS
Focal segmental glomerulosclerosis
MCD
Minimal change disease
Nephrotic syndrome
Accés en línia:http://link.springer.com/article/10.1186/s12882-020-01797-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars